Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)

Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology 2017, Vol.47 (1), p.102-106
Main Authors: Popova, E. V., Boiko, A. N., Boiko, O. V.
Format: Article
Language:English
Subjects:
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Comparative studies
Multiple sclerosis
Neurobiology
Neurosciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4742-717569f4744848aee8d15347414f46f678ad623a770c3fd1cc666b85fe4afd283
cites cdi_FETCH-LOGICAL-c4742-717569f4744848aee8d15347414f46f678ad623a770c3fd1cc666b85fe4afd283
container_end_page 106
container_issue 1
container_start_page 102
container_title Neuroscience and behavioral physiology
container_volume 47
creator Popova, E. V.
Boiko, A. N.
Boiko, O. V.
description Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line agents are used in this situation, which on the territories of the Russian Federation include fingolimod. Experience in the use of fingolimod in routine neurological practice was obtained by performing the postmarketing GIMN trial.
doi_str_mv 10.1007/s11055-016-0370-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1868319574</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1947466985</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4742-717569f4744848aee8d15347414f46f678ad623a770c3fd1cc666b85fe4afd283</originalsourceid><addsrcrecordid>eNp1kUFvFSEUhYnRxGf1B7gjcfO6GIUZBpiledFnk9aa15q4I3Tm0tIwMAKjef1V_Ykyjgtj4grI_c45lxyEXlPylhIi3iVKSdtWhPKKNIJU9RO0oa1oKtl1356iDSGdqEjLuufoRUr3pGiEJBv0eIA0u5xwMFjjg_ZDGO0DDPhyAo8vysj24DNEvAvjpKPO9gfgqzwPx0WS7wBfBwdR31hn8xEXA3ylDeTf47114I8ab431t8HZMQyn2Hr8pdgU14R_2nyHDzDanAux5k2uBPTFMySb8HaJ2J9dfMZpCT19iZ4Z7RK8-nOeoK8fP1zvPlXnl_uz3fvzqmeC1ZWgouWdKXcmmdQAcqBtU56UGcYNF1IPvG60EKRvzED7nnN-I1sDTJuhls0J2q6-UwzfZ0hZjTb14Jz2EOakqOSyoV0rWEHf_IPehzn6sp2iXYnkvJNtoehK9eVjKYJRU7SjjkdFiVo6VGuHqnSolg5VXTT1qkmF9bcQ_3L-r-gXstqgJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1947466985</pqid></control><display><type>article</type><title>Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)</title><source>Springer Link</source><creator>Popova, E. V. ; Boiko, A. N. ; Boiko, O. V.</creator><creatorcontrib>Popova, E. V. ; Boiko, A. N. ; Boiko, O. V. ; for the study group</creatorcontrib><description>Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line agents are used in this situation, which on the territories of the Russian Federation include fingolimod. Experience in the use of fingolimod in routine neurological practice was obtained by performing the postmarketing GIMN trial.</description><identifier>ISSN: 0097-0549</identifier><identifier>EISSN: 1573-899X</identifier><identifier>DOI: 10.1007/s11055-016-0370-2</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Behavioral Sciences ; Biomedical and Life Sciences ; Biomedicine ; Comparative studies ; Multiple sclerosis ; Neurobiology ; Neurosciences</subject><ispartof>Neuroscience and behavioral physiology, 2017, Vol.47 (1), p.102-106</ispartof><rights>Springer Science+Business Media New York 2016</rights><rights>Neuroscience and Behavioral Physiology is a copyright of Springer, 2016.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4742-717569f4744848aee8d15347414f46f678ad623a770c3fd1cc666b85fe4afd283</citedby><cites>FETCH-LOGICAL-c4742-717569f4744848aee8d15347414f46f678ad623a770c3fd1cc666b85fe4afd283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Popova, E. V.</creatorcontrib><creatorcontrib>Boiko, A. N.</creatorcontrib><creatorcontrib>Boiko, O. V.</creatorcontrib><creatorcontrib>for the study group</creatorcontrib><title>Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)</title><title>Neuroscience and behavioral physiology</title><addtitle>Neurosci Behav Physi</addtitle><description>Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line agents are used in this situation, which on the territories of the Russian Federation include fingolimod. Experience in the use of fingolimod in routine neurological practice was obtained by performing the postmarketing GIMN trial.</description><subject>Behavioral Sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Comparative studies</subject><subject>Multiple sclerosis</subject><subject>Neurobiology</subject><subject>Neurosciences</subject><issn>0097-0549</issn><issn>1573-899X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kUFvFSEUhYnRxGf1B7gjcfO6GIUZBpiledFnk9aa15q4I3Tm0tIwMAKjef1V_Ykyjgtj4grI_c45lxyEXlPylhIi3iVKSdtWhPKKNIJU9RO0oa1oKtl1356iDSGdqEjLuufoRUr3pGiEJBv0eIA0u5xwMFjjg_ZDGO0DDPhyAo8vysj24DNEvAvjpKPO9gfgqzwPx0WS7wBfBwdR31hn8xEXA3ylDeTf47114I8ab431t8HZMQyn2Hr8pdgU14R_2nyHDzDanAux5k2uBPTFMySb8HaJ2J9dfMZpCT19iZ4Z7RK8-nOeoK8fP1zvPlXnl_uz3fvzqmeC1ZWgouWdKXcmmdQAcqBtU56UGcYNF1IPvG60EKRvzED7nnN-I1sDTJuhls0J2q6-UwzfZ0hZjTb14Jz2EOakqOSyoV0rWEHf_IPehzn6sp2iXYnkvJNtoehK9eVjKYJRU7SjjkdFiVo6VGuHqnSolg5VXTT1qkmF9bcQ_3L-r-gXstqgJA</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Popova, E. V.</creator><creator>Boiko, A. N.</creator><creator>Boiko, O. V.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7TK</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>2017</creationdate><title>Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)</title><author>Popova, E. V. ; Boiko, A. N. ; Boiko, O. V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4742-717569f4744848aee8d15347414f46f678ad623a770c3fd1cc666b85fe4afd283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Behavioral Sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Comparative studies</topic><topic>Multiple sclerosis</topic><topic>Neurobiology</topic><topic>Neurosciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Popova, E. V.</creatorcontrib><creatorcontrib>Boiko, A. N.</creatorcontrib><creatorcontrib>Boiko, O. V.</creatorcontrib><creatorcontrib>for the study group</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Neuroscience and behavioral physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Popova, E. V.</au><au>Boiko, A. N.</au><au>Boiko, O. V.</au><aucorp>for the study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)</atitle><jtitle>Neuroscience and behavioral physiology</jtitle><stitle>Neurosci Behav Physi</stitle><date>2017</date><risdate>2017</risdate><volume>47</volume><issue>1</issue><spage>102</spage><epage>106</epage><pages>102-106</pages><issn>0097-0549</issn><eissn>1573-899X</eissn><abstract>Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line agents are used in this situation, which on the territories of the Russian Federation include fingolimod. Experience in the use of fingolimod in routine neurological practice was obtained by performing the postmarketing GIMN trial.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11055-016-0370-2</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0097-0549
ispartof Neuroscience and behavioral physiology, 2017, Vol.47 (1), p.102-106
issn 0097-0549
1573-899X
language eng
recordid cdi_proquest_miscellaneous_1868319574
source Springer Link
subjects Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Comparative studies
Multiple sclerosis
Neurobiology
Neurosciences
title Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A59%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20a%20Randomized%20Open%20Multicenter%20Comparative%20Study%20of%20the%20Tolerability%20and%20Safety%20of%20Gilenya%20(fingolimod)%20in%20Patients%20with%20Remitting%20Multiple%20Sclerosis%20(the%20GIMN%20study)&rft.jtitle=Neuroscience%20and%20behavioral%20physiology&rft.au=Popova,%20E.%20V.&rft.aucorp=for%20the%20study%20group&rft.date=2017&rft.volume=47&rft.issue=1&rft.spage=102&rft.epage=106&rft.pages=102-106&rft.issn=0097-0549&rft.eissn=1573-899X&rft_id=info:doi/10.1007/s11055-016-0370-2&rft_dat=%3Cproquest_cross%3E1947466985%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4742-717569f4744848aee8d15347414f46f678ad623a770c3fd1cc666b85fe4afd283%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1947466985&rft_id=info:pmid/&rfr_iscdi=true